Friday 7 May 2021
Home      All news      Contact us      RSS      India
orissadiary.com - 16 days ago

Bharat Biotech and ICMR Announce Interim Results from Phase 3 trials of COVAXIN®; Demonstrates overall Interim Clinical Efficacy of 78% and 100% efficacy against Severe COVID-19 disease

Hyderabad: Bharat Biotech, a global leader in vaccine innovation, developing vaccines for infectious diseases, announced phase 3 interim analysis results of COVAXIN®. The second interim analysis is based on accruing more than 87 symptomatic cases of COVID-19. Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of [ ]


Latest News
Hashtags:   

Bharat

 | 

Biotech

 | 

Announce

 | 

Interim

 | 

Results

 | 

Phase

 | 

trials

 | 

COVAXIN®

 | 

Demonstrates

 | 

overall

 | 

Interim

 | 

Clinical

 | 

Efficacy

 | 

efficacy

 | 

against

 | 

Severe

 | 

COVID

 | 

disease

 | 

Sources